Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Abionyx Pharma
EvolveImmune Targets Lymphoma With Novel T-Cell Engagers Harnessing CD2
Emerging Company Profile: The firm’s use of the CD2 co-stimulant in its T cell engager design could significantly boost anti-tumor efficacy while addressing T cell exhaustion, with a first-in-human trial planned for 2024.
NextMed Health Or ‘When Burning Man Meets Health Care At The Beach,’ Just Weeks Away
The XMed conference, now NextMed Health, returns to the Hotel del Coronado with packed programming. Health care innovators will join leaders from industry, governments, organizations and academia to discuss the future of health care.
Financing Quarterly Statistics, Q4 2022
During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.
Abionyx Looks To Next Steps As Renal Sepsis Candidate Succeeds At Phase IIa
The French firm’s lead asset has impressed in a Phase IIa trial in sepsis patients at risk of kidney injury, triggering discussions with regulators for a path forward in the challenging and life-threatening condition.
- Other Names / Subsidiaries
- Cerenis Therapeutics, Inc.
- Cerenis Therapeutics Holding SA
- Lypro Biosciences
- Iris Pharma Holding SAS
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.